Literature DB >> 15186599

Radiolabeled annexin-V for monitoring treatment response in oncology.

Christophe Van de Wiele1, Hubert Vermeersch, David Loose, Alberto Signore, Nico Mertens, Rudi Dierckx.   

Abstract

Because of its potential to allow for noninvasive, repetitive, and selective in vivo identification of the site and extent of apoptotic cell death and for monitoring cell death kinetics without the need for invasive biopsy, radiolabeled annexin-V is of major clinical relevance. This paper reviews available preclinical and clinical data on radiolabeled annexin-V pertaining to the domain of monitoring response to radiotherapy and chemotherapy, focusing especially on advantages and drawbacks of the different labeling procedures for the radiolabeling of annexin-V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186599     DOI: 10.1089/108497804323071968

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  4 in total

1.  Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Authors:  Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 2.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

3.  A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.

Authors:  Glenn Liu; Jill Kolesar; Douglas G McNeel; Catherine Leith; Kathy Schell; Jens Eickhoff; Fred Lee; Anne Traynor; Rebecca Marnocha; Dona Alberti; James Zwiebel; George Wilding
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

4.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.